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INTRODUCTION
The effects of obesity and overweight have been studied in
various diseases. It has been known that obesity may cause
diabetes, osteoarthritis, cardiovascular diseases, sleep apnea,
breast and uterine cancers and other reproductive disorders
in women (1-4). Body mass index (BMI) has been widely used
to assess the degree of obesity and overweight objectively and
used as an indicator in many studies.
Detrimental impacts of obesity and overweight on pregnan-
cy and delivery outcomes have long been investigated. Women
with obesity and overweight have higher rates of abortion,
preterm birth, cesarean delivery and neonatal complications
(5, 6). Several hypotheses have been raised regarding an asso-
ciation between lower fecundity rate and obesity or overwei-
ght associated with polycystic ovary syndrome (PCOS) (7-9).
Despite the above mentioned studies, there are only few
reports on the effects of obesity and overweight on the out-
comes of in vitro fertilization and embryo transfer (IVF-ET)
that had reported different results. While some studies report-
ed a decrease in pregnancy and implantation rates in obese
women (10-12), others reported no effects of extreme body
weights (13, 14).
Average BMI and its impact on the IVF-ET can be differ-
ent among different ethnic groups. Recently, a difference in
the outcomes of IVF-ET between African American and white
women was reported with a difference in BMI between the
two (15). The effects of obesity and overweight on the IVF-
ET outcomes are still unknown in Asian ethnic groups. Data
on this is important since the optimal practice and prediction
of prognosis in the treatment of infertile couples may be dif-
ferent among different races. The authors sought to elucidate
the clinical efficacy of BMI as a predictor of IVF-ET outcomes
in Korean women.
MATERIALS AND METHODS
Study subjects
Two hundred and twenty-three IVF-ET cycles using GnRH
agonist long protocols were retrospectively analyzed, and oo-
cyte donation and cryopreserved embryo transfer cycles were
excluded. All subjects were under 37 yr old. BMI (kg/m
2) was
calculated as body weight (kg) divided by height squared
(m
2). The outcomes of IVF-ET were compared between the
two groups: BMI <24 kg/m
2 (group 1) and BMI ≥24 kg/m
2
(group 2).
IVF-ET protocols
Controlled ovarian hyperstimulation (COH) and IVF-ET
was performed as reported previously (16-18). COH was un-
dertaken using subcutaneous triptorelin (Decapeptyl
�; Fer-
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Clinical Efficacy of Body Mass Index as Predictor of In Vitro 
Fertilization and Embryo Transfer Outcomes 
The aim of this study was to evaluate the clinical efficacy of body mass index (BMI)
as a predictor of in vitro fertilization and embryo transfer (IVF-ET) outcomes. Two
hundred twenty-three IVF-ET cycles in 164 patients under 37 yr using GnRH ago-
nist long protocols were included in this retrospective study. All of the selected cases
were divided into two groups by a cutoff of 24 kg/m
2 and these two groups were com-
pared in regard to the outcomes of IVF-ET. There were no significant differences
between group 1 (BMI <24 kg/m
2) and group 2 (BMI ≥24 kg/m
2) in age, basal serum
FSH level, estradiol (E2) level and endometrial thickness on hCG day, number of
retrieved oocytes and transferred embryos. However, higher doses of gonadotropins
were used in group 2 (30.8±12.7 ampoules vs. 35.4±15.3 ampoules, p=0.051).
The clinical pregnancy rate was significantly lower in group 2 (25.9% vs. 10.5%, p=
0.041) and implantation rate tended to be lower in group 2 (12.7% vs. 6.8%, p=
0.085). BMI ≥24 kg/m
2 can be a candidate prognosticator of IVF-ET outcomes.
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ring, Sweden) in a long protocol combined with FSH (Metro-
din HP
�; Serono, Switzerland). Treatment with triptorelin
(0.1 mg/day) began on day 21 of the preceding cycle and con-
tinued until the day of hCG treatment. As for the women
with irregular menstrual cycles such as PCOS women, recei-
ved GnRHa treatment with progesterone withdrawal. Treat-
ment with 2-4 ampules of FSH, depending on the patients’
previous or anticipated responses, was initiated on day 3 of
the menstrual cycle. The treatment was then individualized
and adjusted according to the response. When the leading
follicle reached 18 mm in mean diameter with a serum estra-
diol (E2) level of 200 pg/mL per mature follicle, 10,000 IU
of hCG (Profasi
�; Serono, Switzerland) was administered. Oo-
cyte retrieval was performed 36 hr after the hCG injection.
The intracytoplasmic sperm injection (ICSI) was performed
according to conventional protocols and only on the MII oo-
cytes. Up to four embryos were transferred vaginally on the
second or third day after retrieval. The luteal phase was sup-
ported by intramuscular progesterone. Cumulative embryo
score (CES) was calculated as the number of blastomeres mul-
tiplied by the quality of embryo (I-V/V) and used as an indi-
cator of implantation potential. Clinical pregnancy was diag-
nosed when fetal cardiac activity was confirmed by ultraso-
nography at 3-4 weeks after embryo transfer.
Statistical analysis
All data were analyzed using SPSS ver. 9.0.1. Student’s t-
test and chi-square tests were employed as appropriate. p
value <0.05 was regarded as statistically significant. 
RESULTS
One hundred and eighty-five and 38 cycles fell into the
group 1 (BMI <24 kg/m
2) and group 2 (BMI ≥24 kg/m
2),
respectively. There was no difference in their clinical charac-
teristics such as age, number of cycles and basal FSH levels
between the two groups (Table 1).
No differences were observed in terms of peak E2 concentra-
tions, endometrial thickness, number of retrieved oocytes and
transferred embryos and cumulative embryo scores. However,
higher doses of gonadotropins were used in group 2 (30.8±
12.7 ampoules vs. 35.4±15.3 ampoules, p=0.051). Clinical
pregnancy rate was significantly higher in group 1 (25.9% vs.
10.5%, p=0.041). Implantation rate was also higher in group
1 (12.7% vs. 6.8%, p=0.085) (Table 2).
DISCUSSION
Various measures have been used to assess the degree of obe-
sity and overweight including BMI, waist circumference (WC)
and waist-hip ratio (WHR). WC is used to assess abdominal
obesity, WHR to assess central adiposity, and BMI to assess
general body composition (19, 20). 
World Health Organization (WHO) defines 18.5 kg/m
2 to
24 kg/m
2 as ‘normal’, 25 kg/m
2 to 30 kg/m
2 as ‘pre-obese’
and higher than 30 kg/m
2 as ‘obese’. However, these criteria
may not be adequate to be used in Asian women, and this
necessitates provision of different standards (21-23). 
The average BMI of study subjects was 21.2±2.8 kg/m
2
(mean±S.D.), and as described previously, BMI of 24 kg/m
2
was used as cutoff in this study. With this cutoff, only 38 cycles
corresponded to high BMI group (group 2). A cutoff of 25
kg/m
2 as in the WHO criteria may be inadequate as a prog-
nostic indicator in IVF-ET cycles of Korean women since the
distribution of BMI differs according to ethnicity and envi-
ronment.
Underweight has also been known to negatively affect the
outcomes of IVF-ET (24). Nichols et al. reported the harm-
ful impact of both extremes of BMI on the IVF-ET outcomes
(11, 25). From the data of our study subjects, BMI <18 kg/m
2
showed a trend of lower pregnancy rates compared to BMI
Values are expressed as mean±standard deviation. 
*Distributions of infertility factors are not significantly different between
the two groups. 
BMI <24 kg/m
2 BMI ≥24 kg/m
2
Number of women 185 38
BMI (kg/m
2) 20.3±1.8 25.6±1.6
Age (yr) 32.3±3.2 33.3±3.0
Basal FSH (IU/L) 9.6±5.8 7.1±3.3
No. of cycles 2.3±1.5 2.3±1.9
Infertility Factor*
Ovulatory 4 (2.2%) 1 (2.6%)
Tubal  73 (39.5%) 16 (42.1%)
Peritoneal  42 (22.7%) 5 (13.2%)
Uterine 11 (5.9%) 1 (2.6%)
Male 24 (13.0%) 9 (23.7%)
Unexplained 14 (7.6%) 1 (2.6%)
Others 17 (9.2%) 5 (13.2%)
Table 1. Clinical characteristics between the women with BMI
<24 kg/m
2 and those with BMI ≥24 kg/m
2
Values are expressed as mean±standard deviation. 
CES, cumulative embryo score; NS, not significant.
No. BMI <24 kg/m
2 BMI ≥24 kg/m
2 p-value
E2 on hCG day (pg/mL) 1,685.3±1,341.9 1,894.5±1,449.8 NS
Endometrial thickness (mm) 11.3±2.1 11.7±2.2 NS
Dose of gonadotropins 30.8±12.7 35.4±15.3 0.051
used (ampoules)
Oocytes retrieved 9.9±5.8 11.7±8.8 NS
Embryos transferred 3.4±1.0 3.4±0.9 NS
CES 48.6±25.6 50.1±26.8 NS
Clinical pregnancy rate (%) 25.9 (48/185) 10.5 (4/38) 0.041
Implantation rate (%) 12.7 6.8 0.085
Table 2. IVF-ET outcomes between the women with BMI <24
kg/m
2 and those with BMI ≥24 kg/m
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≥18 kg/m
2 group (data not shown). When subjects of BMI
<18 kg/m
2 were eliminated from the group of BMI <24 kg/
m
2, the difference in pregnancy rate became more significant
(p=0.027). 
The mechanism of the effects of BMI is uncertain. From
oocyte donation model, Wattanakumtornkul et al. reported
no difference in the endometrial thickness among women
with different BMI (26). Wang et al. reported that the quali-
ty of transferred embryos was worse in higher BMI women
(27). With these reports and ours that also showed no differ-
ence in the endometrial thickness (Table 2), it may possibly
assumed that BMI affect ovarian folliculogenesis rather than
uterine receptivity.
A higher dose of gonadotropin was necessary in high BMI
group in this study (Table 2). This finding is supported by a
report of Fedorcsak et al. (28). In regard to the underlying
mechanisms, hyperandrogenism and hyperinsulinemia as in
the case of chronic anovulation has been suspected (29). Or
whether this was just due to the gonadotropin concentrations
per unit kg is also subject to further studies.
Intrafollicular hCG concentrations has been studied in rela-
tion to BMI by Carrell et al. (30). BMI was inversely related
to intrafollicular levels of hCG. If this is a significant mech-
anism, an increase in the dose of hCG in higher BMI women
should be considered, which needs to be confirmed by further
studies.
An ethnic difference in the outcomes of IVF-ET was report-
ed between white and African American women (15). In this
report, a difference in the BMI was found between the two
groups. Therefore, it should be differentiated whether the
effects of BMI is confounded by a racial difference. As Kore-
an women are of one nation, comparative studies between
Korean and other Asian women would provide data for the
explanation of the aforementioned findings.
We sought to evaluate the clinical efficacy of BMI as a pre-
dictor of IVF-ET cycles using GnRH agonist long protocols.
With a cutoff of 24 kg/m
2, higher BMI women showed a
decrease in clinical pregnancy and implantation rates and an
increase in the gonadotropin requirement. In Korean women,
a lower cutoff seems to be efficacious in predicting the out-
comes of IVF-ET cycles, rather than the WHO criteria of pre-
obese and obese being ≥25 kg/m
2. Further studies in a larger
scale are necessary to confirm these data and to search the
underlying mechanisms, and to evaluate the effects of BMI
in women using other COH protocols. Whether the weight
control of women with BMI of ≥24 kg/m
2 prior to IVF-ET
cycles has any therapeutic efficacy is also subject to further
investigations.
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